Literature DB >> 9935164

Increased tumorigenicity of rat colon carcinoma cells after alpha1,2-fucosyltransferase FTA anti-sense cDNA transfection.

F Hallouin1, C Goupille, V Bureau, K Meflah, J Le Pendu.   

Abstract

Accumulation of histo-blood group antigens such as Lewis b, Lewis Y and H increases tumor cell motility and tumorigenesis. Alpha1,2-fucosylation is a key step in the synthesis of these antigens. Two alpha1,2-fucosyltransferases, expressed in colorectal carcinomas, have been characterized (FUT1 and FUT2 in humans, FTA and FTB in rats). To define the relative contribution of each of these enzymes in tumor cell behavior, we have used an anti-sense transfection approach in rat colon carcinoma PROb cells, which synthesize mRNA encoding for both enzymes. We have previously reported that anti-sense transfection of a cDNA fragment of the FTB enzyme decreased H antigenic cell-surface levels and concomitantly decreased tumorigenicity. H antigens, detected by antibodies specific for H type 1, 3 or 4, were detected only on a splice variant of CD44 containing the product of exon v6. We now report the anti-sense transfection of an FTA cDNA fragment into PROb cells, which resulted in decreased enzymatic activity on a type 2 precursor and decreased cell-surface H type 2 antigen exclusively. Compared to controls, FTA anti-sense-transfected cells were significantly more tumorigenic in syngeneic animals but not in immunodeficient SCID mice. The UEA-I lectin, specific for H type 2, revealed that these structures were present on the CD44v6 variant and on an uncharacterized 80-kDa glycoprotein. Our results indicate that FTA and FTB fucosylate distinct glycan chains in the same cell, leading to opposite effects, under control of the immune system.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 9935164     DOI: 10.1002/(sici)1097-0215(19990209)80:4<606::aid-ijc20>3.0.co;2-m

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  8 in total

Review 1.  The gastrointestinal microbiota and colorectal cancer.

Authors:  Temitope O Keku; Santosh Dulal; April Deveaux; Biljana Jovov; Xuesong Han
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2014-12-24       Impact factor: 4.052

2.  Cell surface fucosylation does not affect development of colon tumors in mice with germline Smad3 mutation.

Authors:  Steven E Domino; David M Karnak; Elizabeth A Hurd
Journal:  Tumour Biol       Date:  2007-01-29

3.  Association of type O blood with pancreatic neuroendocrine tumors in Von Hippel-Lindau syndrome.

Authors:  Allison B Weisbrod; David J Liewehr; Seth M Steinberg; Erin E Patterson; Steven K Libutti; W Marston Linehan; Naris Nilubol; Electron Kebebew
Journal:  Ann Surg Oncol       Date:  2012-02-16       Impact factor: 5.344

4.  A novel role for inducible Fut2 in angiogenesis.

Authors:  Pei-Suen Tsou; Jeffrey H Ruth; Phillip L Campbell; Takeo Isozaki; SolHee Lee; Hubert Marotte; Steven E Domino; Alisa E Koch; Mohammad A Amin
Journal:  Angiogenesis       Date:  2012-10-12       Impact factor: 9.596

5.  α(1,2)fucosylation in human colorectal carcinoma.

Authors:  L Muinelo-Romay; E Gil-Martín; A Fernández-Briera
Journal:  Oncol Lett       Date:  2010-03-01       Impact factor: 2.967

6.  Novel role of O-glycosyltransferases GALNT3 and B3GNT3 in the self-renewal of pancreatic cancer stem cells.

Authors:  Srikanth Barkeer; Seema Chugh; Saswati Karmakar; Garima Kaushik; Sanchita Rauth; Satyanarayana Rachagani; Surinder K Batra; Moorthy P Ponnusamy
Journal:  BMC Cancer       Date:  2018-11-22       Impact factor: 4.430

Review 7.  CD44 Glycosylation as a Therapeutic Target in Oncology.

Authors:  Chengcheng Liao; Qian Wang; Jiaxing An; Jie Chen; Xiaolan Li; Qian Long; Linlin Xiao; Xiaoyan Guan; Jianguo Liu
Journal:  Front Oncol       Date:  2022-07-21       Impact factor: 5.738

Review 8.  Glycosylation of Cancer Stem Cells: Function in Stemness, Tumorigenesis, and Metastasis.

Authors:  Srikanth Barkeer; Seema Chugh; Surinder K Batra; Moorthy P Ponnusamy
Journal:  Neoplasia       Date:  2018-07-06       Impact factor: 5.715

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.